EARNEST Partners’s Neurocrine Biosciences NBIX Stock Holding History

EARNEST Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-28	Closed	-$3.15K	–	803
2023 Q3	$3.15K	Hold	28	–	–	﹤0.01%	917
2023 Q2	$2.64K	Hold	28	–	–	﹤0.01%	952
2023 Q1	$2.83K	Hold	28	–	–	﹤0.01%	931
2022 Q4	$3.34K	Hold	28	–	–	﹤0.01%	895
2022 Q3	$3K	Hold	28	–	–	﹤0.01%	902
2022 Q2	$3K	Hold	28	–	–	﹤0.01%	929
2022 Q1	$3K	Hold	28	–	–	﹤0.01%	953
2021 Q4	$2K	Hold	28	–	–	﹤0.01%	1036
2021 Q3	$3K	Hold	28	–	–	﹤0.01%	967
2021 Q2	$3K	Hold	28	–	–	﹤0.01%	980
2021 Q1	$3K	Hold	28	–	–	﹤0.01%	971
2020 Q4	$3K	Hold	28	–	–	﹤0.01%	951
2020 Q3	$3K	Hold	28	–	–	﹤0.01%	904
2020 Q2	$3K	Hold	28	–	–	﹤0.01%	878
2020 Q1	$2K	Hold	28	–	–	﹤0.01%	902
2019 Q4	$3K	Hold	28	–	–	﹤0.01%	939
2019 Q3	$3K	Hold	28	–	–	﹤0.01%	909
2019 Q2	$2K	Hold	28	–	–	﹤0.01%	1009
2019 Q1	$2K	Hold	28	–	–	﹤0.01%	1017
2018 Q4	$2K	Hold	28	–	–	﹤0.01%	981
2018 Q3	$3K	Hold	28	–	–	﹤0.01%	946
2018 Q2	$3K	Hold	28	–	–	﹤0.01%	946
2018 Q1	$2K	Hold	28	–	–	﹤0.01%	1006
2017 Q4	$2K	Buy	+28	New	+$1.91K	﹤0.01%	1004
2017 Q1	–	Sell	-28	Closed	-$1K	–	664
2016 Q4	$1K	Buy	+28	New	+$1.27K	﹤0.01%	1050

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EARNEST Partners's NBIX Position: Q4 2023 in Review

EARNEST Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 28 shares — an estimated $3.15K sold.

EARNEST Partners first reported a position in NBIX in Q4 2016 and held it in 25 quarters. The position peaked at $3.34K in Q4 2022. 555 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

EARNEST Partners reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 28 Neurocrine Biosciences shares in Q4 2023, an estimated $3.15K.
EARNEST Partners first reported a position in Neurocrine Biosciences in Q4 2016 and held it in 25 quarters.
EARNEST Partners's Neurocrine Biosciences position peaked at $3.34K in Q4 2022.
555 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.